L-type Ca2+ channel modulation of beta cell function
L 型 Ca2 通道调节 β 细胞功能
基本信息
- 批准号:8292152
- 负责人:
- 金额:$ 27.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-04-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adenylate CyclaseAgonistAmino Acid SequenceBeta CellBindingBiological AssayBlood GlucoseCell LineCell ProliferationCell modelCell physiologyCellsChemosensitizationComplexCouplingCyclic AMPCyclic AMP-Dependent Protein KinasesDataDevelopmentDihydropyridinesElectrophysiology (science)EnvironmentEventExocytosisExtracellular DomainFluorescenceFluorescence MicroscopyGTP-Binding ProteinsGlucoseGoalsHormonesHyperglycemiaImageImmunoprecipitationInsulinIslets of LangerhansKnock-in MouseL-Type Calcium ChannelsLeadLigand BindingLinkMediatingMethodsMolecularNon-Insulin-Dependent Diabetes MellitusOutputPathway interactionsPatternPeptide ReceptorPeptidesPharmaceutical PreparationsPhosphorylationPhysiologicalProinsulinPropertyProteinsRattusReceptor ActivationRoleSignal PathwaySignal TransductionStimulusStructureStructure of beta Cell of isletSystemTechniquesViral VectorWestern BlottingWorkchannel blockersdihydropyridineglucagon-like peptide 1insulin granuleinsulin secretioninsulinomaknock-downmutantnovelpatch clamppeptide Bpreferencepreventprotein protein interactionprototypereceptorresponsesensorsmall molecule
项目摘要
Project Summary
In type II diabetes, the insulin secreting beta cells of pancreatic islets fail to secrete insulin in sufficient
quantities to maintain normal blood glucose levels. The resulting hyperglycemia can lead to many serious
complications. Therefore, understanding the mechanisms that mediate insulin secretion could lead to new
therapies to prevent the onset and complications of Type II diabetes. Two sub-classes of L-type calcium
channels, Cav1.2 and Cav1.3 are expressed in pancreatic beta cells. We have developed a "knock in" method to
introduce Cav1.2 and Cav1.3 mutant channels that are insensitive to the dihydropyridine (DHP) class of L-type
channel blockers into the insulinoma cell line INS-1. In this system, the endogenous L-type channels can be
"shut off" with DHP drugs, thus pharmacologically isolating either Cav1.2 of Cav1.3 channels. Using this
system, we have shown that Cav1.3 but not Cav1.2 channels can mediate glucose-stimulated insulin secretion.
Insulin secretion is potentiated by the hormone GLP-1, by its binding to the GLP-1 receptor. We have
identified a short peptide, derived from the GLP-1 receptor primary amino acid sequence, that can mimic some,
but not all of the actions of GLP-1. We hypothesize that in the context of the receptor this peptide comprises an
autoactivation domain that is unmasked upon ligand binding. In Aim 1 of this project, we will characterize both
the activity of this peptide as a small molecule agonist, and its contribution to GLP-1 receptor activation in the
context of the GLP-1 receptor structure. In Aim 2, we will further examine the mechanisms that couple L-type
calcium channels to insulin secretion and beta cell proliferation, and how they are modulated by GLP-1 receptor
activation. Although most of this work will be done in the INS-1 cell model, viral vectors have been developed
to introduce mutant channels and channel fragments into rat primary beta cells. This proposal will utilize
techniques such as patch clamp whole-cell electrophysiology, Fluorescence Lifetime Imaging, Total Internal
Reflection Fluorescence Microscopy, insulin secretion assays, immunoprecipitation assays, and western blot
assays. This proposal is consistent with the PI's long term goal of understanding L-type calcium channel
modulation and cellular function.
项目摘要
在II型糖尿病中,胰岛分泌胰岛素的β细胞不能分泌足够的胰岛素。
维持正常血糖水平所需的数量。由此产生的高血糖可导致许多严重的
并发症。因此,了解调节胰岛素分泌的机制可能会导致新的
预防II型糖尿病发病和并发症的治疗。L型钙的两个亚类
通道、Cav1.2和Cav1.3在胰岛β细胞中表达。我们开发了一种“敲进去”的方法来
引入对L类二氢吡啶不敏感的Cav1.2和Cav1.3突变通道
通道阻滞剂进入胰岛素瘤细胞系INS-1。在这个系统中,内生的L式的经络可以
用DHP药物“关闭”,从而从药理上隔离Cav1.2或Cav1.3通道。使用这个
系统中,我们已经证明Cav1.3而不是Cav1.2通道可以介导葡萄糖刺激的胰岛素分泌。
荷尔蒙GLP-1通过与GLP-1受体结合来增强胰岛素的分泌。我们有
鉴定出一种来源于GLP-1受体初级氨基酸序列的短肽,它可以模仿一些,
但并不是GLP-1的所有作用。我们假设,在受体的上下文中,该肽包括一个
配体结合时未被屏蔽的自动激活结构域。在本项目的目标1中,我们将对两者进行描述
该多肽作为小分子激动剂的活性及其在GLP-1受体激活中的作用
GLP-1受体结构的背景。在目标2中,我们将进一步研究L类型的耦合机制
钙通道对胰岛素分泌和β细胞增殖的影响及其受GLP-1受体的调节
激活。虽然大部分工作将在INS-1细胞模型中完成,但已开发出病毒载体
将突变通道和通道片段导入大鼠原代β细胞。这项建议将利用
膜片钳全细胞电生理学、荧光寿命成像、全内
反射荧光显微镜、胰岛素分泌试验、免疫沉淀试验和蛋白质印迹
化验。这一建议与PI了解L型钙通道的长期目标是一致的
调制和细胞功能。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Uncoupling of Cav1.2 from Ca(2+)-induced Ca(2+) release and SK channel regulation in pancreatic β-cells.
Cav1.2 与 Ca(2 ) 诱导的 Ca(2 ) 释放和胰腺 β 细胞中 SK 通道调节的解偶联。
- DOI:10.1210/me.2013-1094
- 发表时间:2014
- 期刊:
- 影响因子:0
- 作者:Wang,Yuchen;Jarrard,RachelE;Pratt,EvanPS;Guerra,MarcyL;Salyer,AmyE;Lange,AllisonM;Soderling,IanM;Hockerman,GregoryH
- 通讯作者:Hockerman,GregoryH
Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx.
EPAC 选择性 cAMP 类似物在 INS-1 细胞中增强磺酰脲作用:甲苯磺丁脲和格列齐特的比较以及 EPAC 激活 2-APB 敏感 Ca2 流入的潜在作用。
- DOI:10.1124/mol.112.081943
- 发表时间:2013
- 期刊:
- 影响因子:3.6
- 作者:Jarrard,RachelE;Wang,Yuchen;Salyer,AmyE;Pratt,EvanPS;Soderling,IanM;Guerra,MarcyL;Lange,AllisonM;Broderick,HilaryJ;Hockerman,GregoryH
- 通讯作者:Hockerman,GregoryH
Antibody inhibition of synaptosomal protein of 25 kDa (SNAP-25) and syntaxin 1 reduces rapid exocytosis in insulin-secreting cells.
25 kDa 突触体蛋白 (SNAP-25) 和突触蛋白 1 的抗体抑制可减少胰岛素分泌细胞中的快速胞吐作用。
- DOI:10.1677/jme.1.01978
- 发表时间:2006
- 期刊:
- 影响因子:3.5
- 作者:Vikman,Jenny;Ma,Xiaosong;Hockerman,GregoryH;Rorsman,Patrik;Eliasson,Lena
- 通讯作者:Eliasson,Lena
Ca2+ influx through L-type Ca2+ channels and Ca2+-induced Ca2+ release regulate cAMP accumulation and Epac1-dependent ERK 1/2 activation in INS-1 cells.
Ca2 通过 L 型 Ca2 通道流入和 Ca2 诱导的 Ca2 释放调节 INS-1 细胞中 cAMP 积累和 Epac1 依赖性 ERK 1/2 激活。
- DOI:10.1016/j.mce.2015.09.034
- 发表时间:2016
- 期刊:
- 影响因子:4.1
- 作者:Pratt,EvanPS;Salyer,AmyE;Guerra,MarcyL;Hockerman,GregoryH
- 通讯作者:Hockerman,GregoryH
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GREGORY Howard HOCKERMAN其他文献
GREGORY Howard HOCKERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GREGORY Howard HOCKERMAN', 18)}}的其他基金
Differential Modulation of Cav1.2 and Cav1.3
Cav1.2和Cav1.3的差分调制
- 批准号:
9298000 - 财政年份:2017
- 资助金额:
$ 27.94万 - 项目类别:
L-type Ca2+ Channel Modulation of Beta Cell Function
L 型 Ca2 通道对 β 细胞功能的调节
- 批准号:
6771332 - 财政年份:2004
- 资助金额:
$ 27.94万 - 项目类别:
L-type Ca2+ Channel Modulation of Beta Cell Function
L 型 Ca2 通道对 β 细胞功能的调节
- 批准号:
7173793 - 财政年份:2004
- 资助金额:
$ 27.94万 - 项目类别:
L-type Ca2+ channel modulation of beta cell function
L 型 Ca2 通道调节 β 细胞功能
- 批准号:
7925825 - 财政年份:2004
- 资助金额:
$ 27.94万 - 项目类别:
L-type Ca2+ Channel Modulation of Beta Cell Function
L 型 Ca2 通道对 β 细胞功能的调节
- 批准号:
7348317 - 财政年份:2004
- 资助金额:
$ 27.94万 - 项目类别:
L-type Ca2+ Channel Modulation of Beta Cell Function
L 型 Ca2 通道对 β 细胞功能的调节
- 批准号:
7010735 - 财政年份:2004
- 资助金额:
$ 27.94万 - 项目类别:
L-type Ca2+ Channel Modulation of Beta Cell Function
L 型 Ca2 通道对 β 细胞功能的调节
- 批准号:
6874870 - 财政年份:2004
- 资助金额:
$ 27.94万 - 项目类别:
L-type Ca2+ channel modulation of beta cell function
L 型 Ca2 通道调节 β 细胞功能
- 批准号:
7735961 - 财政年份:2004
- 资助金额:
$ 27.94万 - 项目类别:
L-type Ca2+ channel modulation of beta cell function
L 型 Ca2 通道调节 β 细胞功能
- 批准号:
8098808 - 财政年份:2004
- 资助金额:
$ 27.94万 - 项目类别:
PHENYLALKYLAMINE BINDING SITE IN L TYPE CALCIUM CHANNELS
L 型钙通道中的苯烷基胺结合位点
- 批准号:
2213376 - 财政年份:1994
- 资助金额:
$ 27.94万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 27.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 27.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 27.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)